# Impact of Ribociclib on Head and Neck Squamous Cell Cancer

> **NCT03179956** · EARLY_PHASE1 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT03179956
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-02
- **Primary completion:** 2018-11-12
- **Final completion:** 2019-01-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179956, "Impact of Ribociclib on Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03179956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*